ENTITY
Bristol Myers Squibb Co

Bristol Myers Squibb Co (BMY US)

236
Analysis
Health CareUnited States
Bristol-Myers Squibb Company is a global biopharmaceutical company. The Company develops, licenses, manufactures, markets, and sells pharmaceutical and nutritional products. Bristol-Myers Squibb products and experimental therapies address cancer, heart disease, HIV/AIDS, diabetes, rheumatoid arthritis, hepatitis, organ transplant rejection, and psychiatric disorders.
more
bullishAntengene
03 Nov 2020 17:43

Antengene IPO Initiation: Hunting for a Cure

Leveraging the management team’s expertise, Antegene focuses on the haematology and oncology therapeutic areas. Overall, we believe that Antegene’s...

Logo
313 Views
Share
bullishJW Therapeutics
24 Oct 2020 16:14

JW Therapeutics IPO: Valuation Insights

The core drug candidate’s competitive advantage in the China CAR-T market, a good cornerstone investor lineup and our valuation analysis suggest...

Logo
451 Views
Share
bullishJW Therapeutics
22 Oct 2020 15:14

JW Therapeutics IPO Initiation: Potent Medicine

JW’s core drug candidate’s competitive advantage is supported by its potential best-in-class safety profile with competitive efficacy, physicians’...

Logo
374 Views
Share
10 Oct 2020 17:29

Simcere Pharmaceutical IPO Initiation: A Rough Patch?

The timing of the IPO is not ideal as Simcere is coming off a weak 1H20. However, Simcere is putting in place the right measures to ensure that the...

Logo
390 Views
Share
17 Sep 2020 01:38

JHBP Holdings (Genor Biopharma) IPO Initiation: Hunting for a Cure

$ Genor Biopharma is a biopharmaceutical company focusing on developing and commercializing oncology and autoimmune drugs. Its drug candidates...

Logo
451 Views
Share
x